The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today. Dimethyl ...
Back from the ECTRIMS 2025 conference in Barcelona, Dr Jiwon Oh reports on several promising results from relapsing-remitting multiple sclerosis (RRMS) clinical trials. A UK phase 2 study showed that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback